In the BioHarmony Drug Report Database
Nebivolol
Bystolic (nebivolol) is a small molecule pharmaceutical. Nebivolol was first approved as Bystolic on 2007-12-17. It is used to treat malignant hypertension in the USA. It is known to target beta-3 adrenergic receptor, beta-2 adrenergic receptor, and beta-1 adrenergic receptor. Bystolic’s patent is valid until 2021-12-17 (FDA).
Trade Name
|
Bystolic |
|---|---|
Common Name
|
nebivolol |
ChEMBL ID
|
CHEMBL434394 |
Indication
|
malignant hypertension |
Drug Class
|
Beta-blockers (propranolol type) |
Image (chem structure or protein)